Abstract of the Talk
For improving efficacy and safety profiles of various pharmaceuticals, Immunwork is developing a T-E technology platform to generate novel therapeutic molecules (including antibody drug conjugates, bispecific Abs, and other multi-functional biologics) containing both targeting (T) and effector (E) moieties. The moieties are prepared separately based on multi-arm linker units and joined by click chemistry. The modular design feature of T-E platform allows the development of a class of new pharmaceuticals (T-E drugs) for potential applications in oncology, autoimmune diseases, infectious diseases, and beyond.
Biography
Tse Wen Chang, is Founder and President of Immunwork, Inc., Taipei, Taiwan, and Distinguished Visiting Chair of Genomics Research Center, Academia Sinica. He cofounded Tanox in Houston, Texas in 1986 and invented in 1987 the anti-IgE therapy, leading to the development of talizumab, omalizumab (Xolair), and ligelizumab. Xolair has been approved for treating severe allergic asthma and chronic spontaneous urticaria. While in Academia Sinica, his group developed FB825, which targets CemX, and UB221, a new form of anti-IgE, which have been respectively licensed to two companies in Taiwan for clinical development. Dr. Chang is now leading Immunwork, Inc. to develop new drugs with both targeting and effector moieties (T-E pharmaceuticals) for applications in various diseases.